1. Home
  2. RDHL vs SNGX Comparison

RDHL vs SNGX Comparison

Compare RDHL & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • SNGX
  • Stock Information
  • Founded
  • RDHL 2009
  • SNGX 1987
  • Country
  • RDHL Israel
  • SNGX United States
  • Employees
  • RDHL N/A
  • SNGX N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDHL Health Care
  • SNGX Health Care
  • Exchange
  • RDHL Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • RDHL 8.2M
  • SNGX 7.4M
  • IPO Year
  • RDHL N/A
  • SNGX 1987
  • Fundamental
  • Price
  • RDHL $5.36
  • SNGX $2.46
  • Analyst Decision
  • RDHL
  • SNGX
  • Analyst Count
  • RDHL 0
  • SNGX 0
  • Target Price
  • RDHL N/A
  • SNGX N/A
  • AVG Volume (30 Days)
  • RDHL 10.1K
  • SNGX 49.5K
  • Earning Date
  • RDHL 04-07-2025
  • SNGX 03-14-2025
  • Dividend Yield
  • RDHL N/A
  • SNGX N/A
  • EPS Growth
  • RDHL N/A
  • SNGX N/A
  • EPS
  • RDHL N/A
  • SNGX N/A
  • Revenue
  • RDHL $3,707,000.00
  • SNGX $364,183.00
  • Revenue This Year
  • RDHL $224.90
  • SNGX N/A
  • Revenue Next Year
  • RDHL $82.69
  • SNGX $76.64
  • P/E Ratio
  • RDHL N/A
  • SNGX N/A
  • Revenue Growth
  • RDHL N/A
  • SNGX N/A
  • 52 Week Low
  • RDHL $5.20
  • SNGX $1.83
  • 52 Week High
  • RDHL $20.28
  • SNGX $14.88
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 34.07
  • SNGX 46.88
  • Support Level
  • RDHL $5.52
  • SNGX $2.25
  • Resistance Level
  • RDHL $5.71
  • SNGX $2.43
  • Average True Range (ATR)
  • RDHL 0.29
  • SNGX 0.15
  • MACD
  • RDHL -0.03
  • SNGX 0.03
  • Stochastic Oscillator
  • RDHL 10.31
  • SNGX 68.97

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: